## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

Claim 1. (original) A multi-dosage liquid pharmaceutical formulation of human growth hormone consisting essentially of human growth hormone at a concentration of from about 5 mg/ml to about 100 mg/ml, 1,2-propylene glycol, an aqueous buffer, a non-ionic surfactant, and a preservative, said pharmaceutical formulation having a tonicity of from about 100 mosm/kg to about 500 mosm/kg and having a pH from about 6.1 and about 6.3.

Claim 2. (original) The pharmaceutical composition according to claim 1, additionally comprising a tonicity-adjusting agent such that the tonicity of the pharmaceutical composition is from about 100 mosm/kg to about 500 mosm/kg.

Claim 3. (previously presented) The pharmaceutical formulation according to claim 1, wherein the concentration of human growth hormone is from about 6 mg/ml to 14 mg/ml.

Claim 4. (canceled)

Claim 5. (previously presented) The pharmaceutical formulation according to claim 1, wherein the concentration of 1,2-proplene glycol is from about 0.5 mg/ml to about 20 mg/ml.

Claim 6. (previously presented) The pharmaceutical formulation according to claim 1, wherein the concentration of 1,2-proplene glycol is from about 5 mg/ml to about 15 mg/ml.

Claim 7. (previously presented) The pharmaceutical formulation according to claim 1, wherein the aqueous buffer is selected from the group consisting of a phosphate buffer, a citrate buffer, an acetate buffer and a formate buffer.

Claim 8. (previously presented) The pharmaceutical formulation according to claim 1, wherein the aqueous buffer is a phosphate buffer.

Claim 9. (canceled)

Claim 10. (canceled)

Claim 11. (canceled)

Claim 12. (previously presented) The pharmaceutical formulation according to claim 1, wherein the non-ionic surfactant is selected from the group consisting of a poloxamer, a Pluronic ® polyol and a polysorbate.

Claim 13. (previously presented) The pharmaceutical formulation according to claim 1, wherein the non-ionic surfactant is a poloxamer.

Claim 14. (canceled)

Claim 15. (previously presented) The pharmaceutical formulation according to claim 1, wherein the non-ionic surfactant is present at a concentration of from about 0.05 to about 4 mg/ml.

Claim 16. (canceled)

Claim 17. (canceled)

Claim 18. (previously presented) The pharmaceutical formulation according to claim 1, wherein the preservative is selected from the group consisting of benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, phenol, benzalkonium chloride, benzethonium chloride, chlorobutanol, 2-phenoxyethanol, phenyl mercuric nitrate and thimerosal.

Claim 19. (canceled)

Claim 20. (canceled)

Claim 21. (currently amended) The pharmaceutical formulation according to claim 24, wherein the optional tonicity-adjusting agent is selected from the group consisting of a sugar, a sugar alcohol, a further polyol, a neutral salt, and an amino acid.

Claim 22. (previously presented) The pharmaceutical formulation according to claim 21, wherein the tonicity-adjusting agent is mannitol.

Claim 23. (previously presented) The pharmaceutical formulation according to claim 1, said pharmaceutical composition being substantially isotonic.

Claim 24. (original) The pharmaceutical formulation according to claim 1, said pharmaceutical composition having a pH of about 6.2.

Claim 25. (previously presented) The pharmaceutical formulation according to claim 1, essentially consisting of 6.67 mg/ml human growth hormone,

from about 6 mg/ml to 15 mg/ml propylene glycol,

10 mM sodium phosphate buffer,

2 mg/mi poloxamer 188,

where necessary mannitol at a concentration sufficient such that the formulation is substantially isotonic,

and having a pH of 6.2.

Claim 26. (previously presented) The pharmaceutical composition according to claim 1, essentially consisting of 6.67 mg/ml human growth hormone,

6 mg/ml propylene glycol,

10 mM sodium phosphate buffer,

22.5 mg/ml mannitol,

2 mg/ml poloxamer 188,

and having a pH of 6.2.

Claim 27. (previously presented) The pharmaceutical composition according to claim 1, essentially consisting of 6.67 mg/ml human growth hormone,

9 mg/ml propylene glycol,

10 mM sodium phosphate buffer,

8.1 mg/mi mannitol,

2 mg/ml poloxamer 188,

and having a pH of 6.2.

Claim 28. (original) The pharmaceutical composition according to claim 1, essentially consisting of 6.67 mg/ml human growth hormone,

12.4 mg/ml propylene glycol,

10 mM sodium phosphate buffer,

2 mg/ml poloxamer 188,

and having a pH of 6.2.

Claim 29. (previously presented) A kit comprising an injection device and a separate container containing a multi-dosage liquid formulation of human growth hormone according to claim 1.